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Injuries to the peripheral nervous system rank among the most common causes of chronic 
neuropathic pain. Afflicting millions of people for months or even years, symptoms of this 
condition have proven difficult to treat clinically. A thorough understanding of the 
pathophysiological changes induced by such nerve lesions is essential to the development of more 
efficient therapeutic options. 
Peripheral nerve injury induces a robust and tightly regulated innate immune response in 
the dorsal horn of the spinal cord. The precise molecular mechanisms regulating the spatiotemporal 
dynamics and functional impact of the response remain incompletely understood. Preclinical 
evidence suggests mitigating this immune response can have a significant therapeutic benefit in 
the treatment of neuropathic pain, however these findings have yet to be clinically validated.  
 To elucidate the mechanisms regulating the spinal immune response, we used a mouse 
model of partial sciatic nerve injury exclusively in male adult (2-3-month-old) mice. The spared 
nerve injury (SNI) model employed throughout our studies induces robust, persistent neuropathic 
pain-like behavior.  
 We established a time course for the spinal immune response to SNI and used mRNA 
extracted from the ipsilateral dorsal horn of lumbar spinal cord segments L4 and L5 to analyze 
changes in the transcriptome at the peak of the immune reaction 7 days after nerve lesion. We 
 discovered upregulation of multiple elements of the triggering receptor expressed on myeloid cells 
2 (Trem2) pathway. Trem2 is considered a regulator of toll-like receptor signaling in innate 
immune cells. It also promotes microglia-mediated phagocytosis in the central nervous system. 
Recent work from our lab has established neuronal apoptosis in the ipsilateral dorsal horn after 
SNI as an essential mechanism leading to the development of chronic neuropathic pain-like 
behavior. We used TUNEL staining of L4 spinal cord sections to compare the clearance of 
apoptotic cell profiles in Trem2-/- mice to wild-type littermates and discovered a key role for Trem2 
in the clearance of apoptotic cells after SNI.  
 We further used genetic deletion of Trem2 as well as administration of a Trem2 agonist in 
C57Bl/6 mice to assess the impact of Trem2 signaling on both the spinal immune response and 
neuropathic pain-like behavior after SNI. Neither removal nor augmentation of Trem2 signaling 
significantly affected the development of neuropathic pain-like behavior. 
 Utilizing flow cytometry, we also evaluated the cellular composition of the spinal immune 
response. We found no evidence that monocytes from the peripheral circulation invade the spinal 
cord after SNI, as has been previously suggested. These findings were corroborated by 
immunohistochemical analysis of spinal cord sections from transgenic mice that express distinct 
fluorescent proteins in their monocyte and microglia cell populations. 
 To better understand the different mechanisms modulating the spinal immune response, we 
further examined several transcriptionally regulated signaling pathways. We achieved the greatest 
reduction of mechanical allodynia in nerve-lesioned mice treated with a P2x4r antagonist. 
Surprisingly, the removal of fractalkine (Cx3cl1) signaling, another prominent chemokine 
signaling pathway in microglia, had no significant impact on either the spinal immune response or 
 mechanical allodynia after SNI. Reducing the number of spinal microglia by blocking Csf1r 
activation did not prevent the development of mechanical allodynia after SNI either.  
 Our findings reveal a more nuanced concept of microglial activation after nerve injury. The 
impact on neuropathic pain-like behavior and phagocytosis appear to be regulated by pathways 
that differ from those controlling immune cell recruitment and global activation. These findings 
provide a greater understanding of the complex mechanisms governing microglial function and 
offer new insight into molecular targets essential to the development of more efficient treatment 
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Our ability to detect potentially harmful and damaging stimuli is essential to human 
survival. The sensation of pain, transmitted from somatosensory nerve fibers to the dorsal horn of 
the spinal cord and then propagated to sensory processing centers in our brain, alerts us to the 
presence of noxious stimuli in internal organs or our surrounding environment. Dysfunction or 
damage to this tightly regulated system of nociception can have severe consequences that 
fundamentally alter the way we experience pain and even normally painless sensations like light 
touch. 
 Neuropathic pain is caused by a lesion or disease affecting the somatosensory nervous 
system (Finnerup et al, 2016) and affects 7-10% of the general population (Bennett et al, 2012; 
van Hecke et al, 2014; DiBonaventura et al, 2017). Common causes include diabetic 
polyneuropathy, herpes zoster and postherpetic neuralgia, trigeminal and other cranial neuralgias, 
cancer chemotherapy, degenerative changes of the spine leading to lumbar radiculopathy and nerve 
trauma. Clinical manifestations of neuropathic pain involve hyperalgesia (heightened or 
exaggerated pain in response to something that is typically only mildly painful) and allodynia (pain 
in response to a normally innocuous stimulus). Neuropathic pain is difficult to address. The 
number of patients needed to be treated (NNT) before one experiences a reduction in pain by at 
least 50% ranges from about 3.6 to 10.6 for the commonly prescribed therapies (see Table 1 from 














Experimental models of neuropathic pain 
 A number of experimental models have been established to better assess the mechanisms 
that lead to neuropathic pain-like behavior. Rodent models of nerve injury-induced neuropathic 
pain are most often utilized, typically involving loose constriction, tight ligation or transection of 
a nerve. 
 While most injury models provoke at least some neuropathic pain-like behaviors that 
mimic clinical symptoms (such as mechanical allodynia or painful hypersensitivity to cold 
stimuli), those involving nerve constriction or ligation may not produce long-lasting pain 
reminiscent of the typically chronic disorders seen in patients (Decosterd and Woolf, 2000). We 
used the spared nerve injury (SNI) model, which involves a combination of ligating and transecting 
the peroneal and tibial branches of the sciatic nerve, leaving the innervation territory of the sural 
Table 1. Efficacy of commonly used pharmacotherapies for the treatment 
of neuropathic pain (adapted from Binder et al, 2016). 
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nerve intact for behavioral testing (Fig 1.1). This model consistently produces persistent 
hypersensitivity in both the rat and mouse (Decosterd and Woolf, 2000; Bourquin et al, 2006). 
Other models have been developed to study the neurotoxic effects of chemotherapy, neuropathies 
associated with type 1 and type 2 diabetes and perineural inflammation.  
 The translational validity of these models is determined by the reproduction of clinically 
relevant pain hypersensitivity. Specific behavioral tests aid in the experimental evaluation of 
neuropathic pain-like behavior. Cold 
hypersensitivity, a common symptom of patients 
with neuropathic pain, is often tested for using 
acetone, a chemical that evaporates rapidly off 
the skin and in the process, produces a cooling 
sensation. Paw withdrawal is interpreted as a 
behavior equivalent to cold allodynia in humans. 
Feeling physical pain from typically innocuous 
mechanical stimuli (mechanical allodynia) is 
often measured using von Frey filaments. The 
filaments range in strength and are applied to the 
affected hindlimb. In uninjured mice, the filaments are generally innocuous until a threshold of 
approximately 1 g. Filaments applying greater force induce withdrawal of the hind paw. 
Mechanical allodynia manifests as a much lower withdrawal threshold. Other behavioral 
paradigms focus on heat sensitivity, which is more relevant to models of nociceptive pain, 





Figure 1.1: Schematic of the spared nerve 
injury (SNI) model of neuropathic pain. 
The tibial and peroneal branches of the 
sciatic nerve are ligated together and 
transected, leaving the sural nerve intact (or 
“spared”). Adapted from Inquimbert et al, 
2018. 
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The immune response to peripheral nerve injury 
 Nerve injury induces profound changes in the excitability and connectivity of neurons both 
in the periphery and CNS (Woolf and Salter, 2000). Damaged nerve terminals are exposed to 
inflammatory mediators released by local immune cells that sensitize the neuronal membrane to 
nociceptive stimuli (Schäfers et al, 2003; Wolf et al, 2006). Increased firing and spontaneous 
activity of primary somatosensory neurons can induce activity-dependent enhancement of 
excitatory neurotransmission at the central terminals of damaged primary afferents, not unlike 
mechanisms of long term potentiation (LTP) observed in the hippocampus (Li et al, 1999; 
Stubhaug et al, 1997). Augmentation of nociceptive transmission is further enhanced by a 
reorganization of central synapses and the extension of newly formed axon terminal collaterals in 
superficial layers of the spinal dorsal horn (Woolf et al, 1992; Kohama et al, 2000). Immune cells, 
both in the damaged peripheral nerve and in the spinal cord, contribute to this process of 
sensitization (Scholz and Woolf, 2007). Elucidating the exact role of glia in the pathological 
amplification of nociceptive sensory information after nerve injury is important for developing 
more efficient pharmacotherapies to treat neuropathic pain.  
 A vivid innate immune response in the ipsilateral dorsal horn of the spinal cord is indeed a 
remarkably conserved phenomenon across models of peripheral nerve lesion. Topically limited to 
the spinal projection territory of damaged afferent nerve fibers, this pattern of neuroinflammation 
in commonly used models of sciatic nerve injury is concentrated in the superficial layers of the 
dorsal horn in lumbar segments L4 and L5. The immune response to peripheral nerve injury 
involves proliferation and activation of local microglia, which are considered the resident 
macrophages of the central nervous system (Tsuda et al, 2005; Watkins and Maier, 2003; DeLeo 
and Yezierski, 2001). Characterized by a sudden upregulation of key microglial activation markers 
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like ionized calcium-binding adaptor molecule 1 (Iba1) and cluster of differentiation 11b (Cd11b), 
these cells shift from their morphologically ramified “resting” state to a more amoeboid, pro-













The exact molecular mechanisms regulating the immune response remain incompletely 
understood. Toll-like receptors (Tlrs) as well as chemokines (Cx3cl1, Ccl2) and purinergic 
signaling have all been suggested as critical modulators of the response. Nerve injury also induces 
significant upregulation of colony stimulating factor 1 (Csf1), an essential microglial growth 
factor, in the injured afferent nerve fibers (Guan et al, 2016). Csf1 is believed to be subsequently 
transported centrally and released into the spinal dorsal horn (Guan et al, 2016). Studies using 
transgenic mice engineered to selectively prevent the injury-induced influx of Csf1 into the spinal 
cord show no increased microglial proliferation or immunoreactivity after nerve injury and exhibit 
Figure 1.2: Nerve injury-induced microglial activation in the mouse 
spinal cord. Ipsilateral dorsal horn of the lumbar spinal cord (segment 
L4). Upregulation of microglial cell markers like Iba1 is accompanied 
by a shift in cellular morphology and transition to a pro-inflammatory 
phenotype (unpublished images). 
Iba1 
Uninjured After SNI 
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largely reduced neuropathic pain-like behavior (Guan et al, 2016). This Csf1-mediated immune 
response also comprises an upregulation of genes implicated in the development of neuropathic 
pain, including Ctss, Irf8 and the purinergic receptor, P2rx4 (Guan et al, 2016).  
One mechanism illustrating the potential of microglia to modulate pain processing involves 
the release of brain-derived neurotrophic factor (Bdnf). Stimulation of microglial P2x4 receptors 
by ATP after peripheral nerve injury drives the increased expression and secretion of Bdnf (Tsuda 
et al, 2003; Ulmann et al, 2008). Bdnf activates tyrosine receptor kinase B (TrkB) on dorsal horn 
neurons, leading to the downregulation of potassium-chloride cotransporter 2 or Kcc2 (Coull et al, 
2005). Kcc2 function is essential for spinal neurons to maintain a low intracellular concentration 
Figure 1.3: Impact of decreased Kcc2 expression on neuronal inhibition. 
TrkB-mediated downregulation of Kcc2 leads to an increased intracellular 
concentration of chloride ions. Consequently, GABAA receptor-mediated 
hyperpolarization, reliant on chloride ion influx, is less effective (scheme from 
Kahle et al, 2014).  
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of chloride ions (Coull et al, 2005; Rivera et al, 2002). Downregulation of Kcc2 leads to a 
depolarizing shift in the anion reversal potential of spinal neurons, compromising the effect of 
inhibitory neurotransmitters GABA and glycine. GABAA and glycine receptor activation typically 
allows for chloride ion influx, hyperpolarization and fast synaptic inhibition of neurons involved 
in pain pathways of the dorsal horn (Coull et al, 2005; see Figure 1.3). These findings have led to 
the development of Kcc2 enhancers as potential analgesics (Kahle et al, 2014; see Figure 1.4). 
 
 
In addition to Bdnf, pro-inflammatory cytokines including interleukin (IL)-1b are known 
to enhance excitatory neurotransmission in dorsal horn neurons (Liu et al, 2013). Tumor necrosis 
factor (TNF)-a has also been shown to increase spontaneous excitatory post-synaptic currents 
(sEPSCs) in dorsal horn neurons (Park et al, 2011).    
Figure 1.4: Proposed mechanism of enhanced Kcc2-mediated chloride extrusion.  
Enhancing neuronal chloride extrusion by increasing the expression of Kcc2 in dorsal horn 
neurons has the potential to restore spinal inhibition and reduce neuropathic pain (scheme 
from Kahle et al, 2014).  
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While traditional approaches to treating neuropathic pain have directly targeted the injury-
induced changes in neuronal processing of nociceptive information, mounting evidence of 
neuroglial interaction suggests the spinal immune response to peripheral nerve injury may in fact 
play a key role in the induction of neuropathic pain. A more thorough understanding of the 
biological function(s) of nerve injury-induced spinal inflammation as well as the molecular 
mechanisms regulating the spatiotemporal dynamics and physiological impact of the response are 




















Trem2-mediated phagocytosis in the spinal cord after peripheral nerve injury 
 
Background and Significance 
Inflammatory pathways regulating the spinal immune response to peripheral nerve injury 
are known to recognize damage-associated molecular patterns (DAMPs). Toll-like receptors, for 
example, bind high mobility group box 1 or Hmgb1 (Park et al, 2004; Yu et al, 2006; Yang et al, 
2018) and heat shock proteins (Vabulas et al, 2002; Dybdahl et al, 2002; Asea et al, 2002).  
In the context of neuropathic pain, the Tlrs identified as key regulators of nerve injury-
induced microglial reactivity include Tlr2 (Kim et al, 2007), Tlr4 (Sorge et al, 2011; Bettoni et al, 
2008; Piao et al, 2018) and Tlr5 (Stokes et al, 2013; Ji et al, 2018).  Genetic deletion of these Tlrs 
provides partial reduction in both the spinal immune response and nerve injury-induced 
mechanical allodynia. All members of the Tlr superfamily recruit the myeloid differentiation 
primary response 88 (MyD88) intracellular adaptor protein to transduce their signal, except for 
Tlr3 which signals instead through the TIR-domain-containing adaptor-inducing interferon-b 
(TRIF) pathway (Yamamoto et al, 2002; Oshiumi et al, 2003; Hoebe et al, 2003; Yamamoto et al, 
2003).  Activation of Tlrs has been shown to induce the downstream p38 mitogen-activated protein 
kinase (MAPK)- and nuclear factor kB (NF-kB)-mediated transcriptional upregulation and release 
of numerous pro-inflammatory cytokines (Gorina et al, 2011). 
Consistent with the involvement of Tlr2, Tlr4 and Tlr5, silencing MyD88 signaling 
(effectively targeting most Tlrs simultaneously) also decreases neuropathic pain-like behavior 
after peripheral nerve injury (Stokes et al, 2013; Liu et al, 2016). These findings have led 
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investigators to consider both endogenous and exogenous inhibition of MyD88-induced immune 
cell activation as a potential focus in the development of novel analgesics. In this context, the 
triggering receptor expressed on myeloid cells 2 (Trem2) pathway, extensively studied in 
macrophages as directly inhibiting lipopolysaccharide (LPS)-induced Tlr4-MyD88 signaling 
(Turnbull et al, 2006; Hamerman et al, 2006; Zhong et al, 2015; Zhang et al, 2017; Zhong et al, 
2017), has recently emerged as a potential therapeutic target in neuropathic pain. 
Trem2 is a 40 kDa transmembrane receptor 
containing an extracellular immunoglobulin variable (IgV) 
domain, a transmembrane domain and a short cytoplasmic 
tail devoid of any substantive signaling motifs (Paradowska-
Gorycka et al, 2013). Trem2 signaling thus depends on the 
formation of a complex at the inner surface of the plasma 
membrane with its primary adaptor protein DNAX-
activating protein of 12 kDa (Dap12). Upon activation of 
Trem2, the immunoreceptor tyrosine activation motif 
(ITAM) on the intracellular region of Dap12 is 
phosphorylated by Src family kinases (Mason et al, 2006). 
This phosphorylation triggers recruitment of downstream 
signaling proteins, including spleen tyrosine kinase or Syk 
(Yao et al, 2016), to regulate immune cell function (Fig. 2.1). 
 Myd88-dependent activation of macrophages by Tlr agonists and the subsequent 
production of inflammatory cytokines is augmented in cells lacking Trem2-Dap12 signaling 
components (Turnbull et al, 2006; Zhong et al, 2017). Similarly, overexpression of Trem2 and 
Figure 2.1: Trem2 forms a 
signaling complex with Dap12 
at the plasma membrane 
(Ulrich et al, 2017). 
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stabilization of the Trem2 signaling complex have been shown to significantly attenuate Tlr-
Myd88-induced cytokine production (Zhang et al, 2017; Ren et al, 2018; Zhong et al, 2015). These 
findings demonstrate the ability of the Trem2-Dap12 pathway to regulate inflammatory immune 
responses in macrophages and microglia. Consequently, the pathway is considered, in part, a 
negative regulator of immune cell activation (Fig. 2.2). 
 
 
Several studies have examined the role of different Tlrs in regulating the spinal immune 
response to peripheral nerve injury, however, the exact function of microglial Trem2 signaling as 
it pertains to nerve injury-induced spinal inflammation and neuropathic pain-like behavior remains 
unclear.  
Figure 2.2: Trem2-Dap12-mediated inhibition of Tlr signaling. Phosphorylated Dap12 
recruits Syk to the Trem2-Dap12 signaling complex, leading to the downstream disruption 
of MyD88-mediated Tlr signaling (Turnbull and Colonna, 2007). 
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Nerve injury-induced apoptosis in the spinal cord 
 In the days and weeks after nerve lesion, apoptotic cell profiles also appear in the ipsilateral 
dorsal horn of the spinal cord (Azkue et al, 1998; Moore et al, 2002; Scholz et al, 2005). Initially 
considered a manifestation of microglial cell turnover (Polgár et al, 2005), it is now clear that the 
induction of apoptosis in fact reflects nerve injury-induced neurodegeneration (Scholz et al, 2005; 
Yowtak et al, 2013). I was actually involved with a study recently published by my research group 
which identified the underlying mechanism of neuronal cell death and determined the functional 
significance for the development of neuropathic pain (Inquimbert et al, 2018). We demonstrated 
that neurons in the ipsilateral dorsal horn undergo excitotoxic cell death after SNI and that 
elimination of functional NMDA receptors through conditional deletion of the essential receptor 
subunit Grin1 (GluN1) prevents this loss of neurons (Figure 2.3). 
Interestingly, the temporal pattern for the emergence of apoptotic profiles after SNI follows 
a remarkably similar time course to the spinal immune response to nerve injury (see Figure 2.3c 
and Figure 2.5). Furthermore, the involvement of inhibitory interneurons in this neuronal apoptosis 
leads to a decrease in GABAergic inhibition of pain pathways and promotes the transition from 























































Figure 2.3: NMDAR-mediated glutamatergic transmission causes nerve injury-induced 
apoptosis.  
(A) Apoptotic cell profiles 7 days after SNI. H33342, Hoechst 33342 (bisbenzimide). Scale bar, 
      10 µm. 
(B) Distribution of apoptotic profiles within the dorsal horn, shown in overlays of 10 sections per 
      Mouse (n=8 mice). 
(C) Time course of apoptosis induction. Apoptotic profiles were counted in 10 sections per mouse 
      (n=8). p<0.001 for surgery and time in a two-way ANOVA. ***p<0.001 in Sidak’s test 
      following the ANOVA. 
(D) GFP expression (left) and in situ hybridization of Grin1 mRNA (right) 3 weeks after injection 
      of the vector into the left dorsal horn of the lumbar (L4) spinal cord of Grin1flox/flox mice 
      eliminated NMDAR function. 
(E) Excitatory currents evoked by NMDA (100 µM) in Grin1flox/flox mice injected with AAV8- 
      GFP or AAV8-GFP-Cre. SNI was performed 2 or 3 weeks after the vector injection. Two 
      weeks after the nerve injury, we compared current amplitudes in the dorsal horn of mice 
      injected with AAV8-GFP (n=5 neurons) or AAV8-GFP-Cre (n=11). ***p<0.001 in 
      Student’s t test. Currents recorded in Grin1flox/flox mice injected with AAV8-GFP did not 
      differ from those in injured C57Bl/6 mice (n=4) or C57Bl/6 mice after SNI (n=6). 
(F) Apoptotic profiles 7 days after SNI in the dorsal horn of Grin1flox/flox mice injected with 
      AAV8-GFP or AAV8-GFP-Cre (n=6 mice). ***p<0.001 in Student’s t test. 
 








































The exact relationship between this neuronal apoptosis and the spinal immune response to 
SNI has yet to be fully elucidated. However, microglia are the primary phagocytes responsible for 
the clearance of cellular debris and apoptotic cells in the CNS (Hu et al, 2015). Thus, the increase 
in apoptosis observed in the dorsal horn after SNI may play a role in the activation of local 
microglia. Trem2, in addition to its suggested immunoregulatory ability, has been implicated as a 
key mechanism by which microglial cells recognize and initiate phagocytosis of apoptotic neurons 
in the CNS (Painter et al, 2015). 
 
Trem2 in neurodegenerative disease 
 Although the endogenous ligand(s) of Trem2 have yet to be precisely identified, a number 
of lipid and lipid-containing molecules linked to cell death, including apolipoprotein E or ApoE 
Figure 2.4: Eliminating functional NMDARs in the dorsal horn blocks the transition from 
acute to chronic neuropathic pain. 
(A and C) Withdrawal responses to (A) mechanical (von Frey filaments) or (C) cold stimulation 
     (acetone evaporation) after sham surgery (n=7 mice) or SNI (n=10) in Grin1flox/flox mice 
     injected with AAV8-GFP-Cre, and SNI in Grin1flox/flox mice injected with AAV8-GFP 
     (n=10). Behavioral outcomes were compared using two-way ANOVAs. p<0.001 for 
     treatment and time in the responses to stimulation with von Frey filaments; p<0.01 for 
     treatment and p<0.001 for time in the acetone test. Asterisks and pound signs indicate 
     the results of Bonferroni’s tests following the ANOVAs. 
(B and D) Areas under the curve (AUCs) were first compared for the total test duration after SNI 
     (p<0.001 for von Frey filaments, B, and acetone test, D, in one-way ANOVAs). 
     Separately, we compared AUCs in the acute phase of the first 7 days after SNI 
     (p<0.001 for both test modalities), during the transition from acute to persistent pain 
     (p<0.001 for the stimulation with von Frey filaments and p<0.05 for the acetone test), 
     and for persistent pain after 21 or 49 days, respectively (p<0.001 for von Frey filaments 
     and p<0.01 for the acetone test). Asterisks and pound signs indicate the results of 
     Tukey’s tests following the ANOVAs. 
*p<0.05, **p<0.01 and ***p<0.001 for the comparison of AAV8-GFP-Cre + SNI and AAV8-
GFP + SNI; #p<0.05, ##p<0.01 and ###p<0.001 for the comparison of AAV8-GFP-Cre + Sham 
and AAV8-GFP-Cre + SNI. Error bars indicate SEM. 
 
Note: Figure and legend from Inquimbert et al, 2018. 
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(Atagi et al, 2015; Bailey et al, 2015; Krasemann et al, 2017) and phosphotidyl serine (Wang et al, 
2015), have been suggested as potential binding partners. In mouse models of Alzheimer’s Disease 
(AD), deficient recognition and clearance of amyloid beta (Ab) fibers by microglia have been 
directly linked to loss-of-function mutations in microglial Trem2 (Kleinberger et al, 2014; Wang 
et al, 2015; Kim et al, 2017; Kober et al, 2016; Zhao et al, 2018; Zhong et al, 2018). Evidence 
from other disease models involving neurodegeneration including stroke (Kawabori et al, 2015) 
and Parkinson’s Disease (Ren et al, 2018) have shown that microglial phagocytosis of apoptotic 
neurons is significantly attenuated when Trem2 signaling is disrupted or compromised.  
 Overexpression of Trem2 has been shown to simultaneously increase microglial 
phagocytosis and decrease the transcription of proinflammatory cytokines (Takahashi et al, 2005). 
Indeed, this dual ability of the Trem2 pathway to aid in the clearance of apoptotic cells and 
extracellular protein aggregates while suppressing inflammation has led investigators to suggest 
that Trem2 activation confers a neuroprotective function of microglia in the context of 
neurodegeneration (Jiang et al, 2016; Zhai et al, 2017; Ren et al, 2018).  
The neuroprotective or homeostatic functions of spinal microglia responding to nerve 
injury have not been previously investigated. Hypothesizing that the spinal immune response may 
involve physiological components in addition to the conventionally observed inflammatory 
effects, we examined the regulation of Trem2 and its signaling partners after SNI. Following our 
recently published finding that neuronal apoptosis is a key mechanism implicated in SNI-induced 
persistent pain, we focused on the role that microglial Trem2 may play in the clearance of nerve 





To determine the time course of the spinal immune response to SNI, we stained spinal cord 
sections from lumbar segment L4 at multiple intervals after SNI for Iba1, a classical marker of 
microglial activation known to participate in actin bundling and membrane ruffling in activated 
microglia and macrophages. L4 represents the region of the spinal cord to which the lesioned 
afferent nerve fibers in the SNI model project and injury-induced inflammation is most 
pronounced. A semi-quantitative analysis of the Iba1 staining intensity showed induction of the 
immune response within 3 days of nerve injury (FC above uninjured controls: 1.8), a peak at 7 
days after SNI (FC: 2.8) and the reversal beginning by day 14 (FC: 2.3). Sections stained at 28 
days after SNI demonstrated no difference in Iba1 immunoreactivity when compared with 

























To better understand the signaling pathways involved in this immune response, we 
conducted an unbiased transcriptome analysis at the peak of the inflammation after SNI. To this 
end, we sequenced mRNA isolated from the L4-L5 ipsilateral dorsal horn of the spinal cord. In 
collaboration with the Columbia Genome Center, we compared the transcripts of C57Bl/6 mice at 
7 days after SNI with those of uninjured controls. Many of the most significantly upregulated genes 
(p<0.01) were established markers of microglial activity (Fig. 2.6), including Itgam (Cd11b; FC: 
3.9), Aif1 (Iba1; FC: 3.1), Cx3cr1 (FC: 2.5) and P2ry12 (FC: 2.2). 
 
Fig 2.5: Time course of the spinal immune 
response to SNI 
(A) Representative immunohistochemical 
       staining for Iba1 in the ipsilateral dorsal 
       horn, L4 spinal cord of C57Bl/6 mice at 
      select intervals after SNI. 
(B) Semi-quantitative analysis of Iba1 signal 
      intensity normalized to uninjured mouse 
       tissue indicated significant increase in Iba1 
      signal after SNI (p<0.01 in one-way 
       ANOVA; n=4; ***p<0.001, **p<0.01, 
      *p<0.05; data represented as mean ± SEM; 







Fig. 2.6: SNI induces a marked upregulation of genes associated with microglial 
activity. Differential expression analysis of transcripts isolated from the ipsilateral 
dorsal horn (L4, L5) 7 days after SNI and uninjured controls. Volcano plots shows 
significantly regulated genes (p<0.01) represented by red dots. Boxed inset identifies 
selected activity-associated genes in blue (n=4). 
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We subjected the complete list of significantly regulated genes (p<0.01) to a gene function 
and pathway analysis using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID; Huang da W et al., 2009). We determined the most prominent gene ontology (GO) terms, 
functions and signaling pathways implicated in the SNI-induced transcriptional changes. Innate 
immune and inflammatory responses including toll-like receptor signaling (all p<0.001) were 


















Fig. 2.7: Pathway analysis of SNI-induced transcriptional changes. Signaling 
pathways and gene ontology (GO) terms for biological processes and molecular 
functions for significantly regulated genes (p<0.01). 
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Indicators of cell damage and phagocytosis 
 Multiple Tlrs and associated signaling molecules were upregulated after SNI between 1.6-
fold (Tlr2; p<0.01) and 4.6-fold (Tlr1; p<0.001) (Figure 2.8). These data support previously 
published work describing the involvement of toll-like receptor signaling in the spinal cord after 





















Fig. 2.8: Upregulation of toll-like receptor 
signaling molecules. 
(A) Volcano plot showing regulated 
       transcripts in red (p<0.01). Tlrs are 
       labeled in the inset.  
(B) Pathway analysis (DAVID) 
       identified toll-like receptor signaling 
       as a significantly upregulated pathway 
       after SNI (p<0.01). Heatmap of genes 
       affiliated with Tlr signaling. 
       Color scale indicates upregulation in red, 




Several Tlrs are known to recognize molecular signals associated with cellular damage 
(DAMPs), many of which emerge in the context of neurodegeneration. Other upregulated gene 
transcripts implicated in the immune response to neuronal apoptosis that we identified included 
Anxa3 (FC: 1.7), Hck (FC: 2.5) and Trem2 (FC: 3.2). Interestingly, the increase in Trem2 
transcription was accompanied by the upregulation of multiple genes associated with Trem2 
signaling, including the intracellular adaptor molecule Dap12 (Tyrobp; FC: 2.5) and the key 
Trem2-Dap12-associated signaling kinase Syk (FC: 2.0). The transcriptional upregulation of 
Trem2 signaling partners was independently verified using quantitative real-time PCR (qRT-PCR; 
Trem2 FC: 3.0, Tyrobp FC: 2.5, Syk FC: 2.2). To further validate the upregulation of Trem2, we 
examined its expression at the protein level. Western blot analysis of protein lysates from the 
ipsilateral L4-L5 dorsal horn showed that, compared with uninjured controls, Trem2 protein 
expression after nerve injury increased 2.4-fold at 3 days after SNI, 3.5-fold at the peak of the 
































































































   



















































   
























   


























   



























   























   


























   


























   


























   
























   
























   















To determine the identity of cells expressing Trem2, we utilized flow cytometry. We 
isolated live cells from L4-L5 dorsal spinal cord and stained them for Trem2 as well as Cd11b and 
Cx3cr1, cell-surface markers exclusively expressed in microglia in the CNS (Fig. 2.10). We found 
that >90% of Trem2+ cells were both Cd11b+ and Cx3cr1+. Control samples counterstained for 
astroglial and neuronal surface markers did not indicate relevant expression levels of Trem2 (not 
shown).  
We additionally conducted immunocytochemical staining on isolated primary microglial 
cells grown in vitro and found that Trem2 colocalized with cells stained for Iba1 (Fig. 2.10), 
confirming microglial expression of the protein in culture. Collectively, these data demonstrate 
that Trem2+ cells are Cd11b+/Cx3cr1+ in vivo and coexpress Iba1 in vitro, effectively localizing 

































Fig. 2.10: Trem2 is expressed in microglia 
(A) Flow cytometric analysis showed that >90% of Trem2+ cells isolated from the mouse spinal 
       cord also express the myeloid specific markers Cd11b and Cx3cr1 (n=4) 
(B) Representative immunocytochemical stains of primary microglial cultures. More than 90% 
       of cells that stained positive for Trem2 also expressed Iba1, indicating the signal was 
       localized to microglia. DAPI was used to stain for cell nuclei. Images are representative of 




Trem2-dependent clearance of apoptotic cells after SNI 
 Facilitating the phagocytosis of apoptotic neurons and cellular debris is a major function 
of the Trem2 signaling pathway in microglia. GO terms and pathway analysis of the most 
significantly regulated genes in our RNA sequencing assay also indicated that phagocytosis is a 
biological process in the spinal cord significantly associated with nerve injury (p=0.011). We 
therefore examined the effect of Trem2 on the clearance of apoptotic cell profiles in the ipsilateral 
dorsal horn after SNI. For this purpose, we utilized Trem2-/- mice kindly provided by Marco 
Colonna at Washington University in St. Louis, MO. 
 Using L4 spinal cord sections harvested at 3 and 7 days after SNI, we stained for apoptotic 
cell profiles using TUNEL. TUNEL-positive cells that also demonstrated chromatin changes 
indicative of apoptosis (specifically pyknosis, marginalization or fragmentation) were considered 
apoptotic. We compared apoptosis in Trem2-/- animals and wild-type controls (Fig. 2.11). We 
found a significantly higher number of apoptotic profiles in the ipsilateral, but not contralateral 
dorsal horn of Trem2-/- mice versus wild-type controls. These results demonstrate a critical role for 
microglial Trem2 in the recognition and clearance of these SNI-induced apoptotic cells in the 
































Fig. 2.11: Trem2 mediates the clearance of apoptotic cell profiles 
(A) Representative image of apoptotic cell profile 7 days after SNI. H33342 
       (Hoechst 33342). Scale bar, 10 µm. 
(B) Gene ontology analysis with DAVID identified phagocytosis as a biological 
       process associated with transcriptional changes in the ipsilateral dorsal horn 
       after SNI. Heatmap of significantly (p<0.01) regulated genes associated with 
       phagocytosis. 
(C and D) Quantification of apoptotic profiles 3 (n=6) and 7 days (n=8) after SNI 
       in the dorsal horn of Trem2-/- mice or wild-type littermates. *p<0.05 in 










Trem2 activation does not modulate neuropathic pain-like behavior 
 Considering the previously reported function of Trem2 as a suppressor of inflammation, 
we investigated whether its upregulation on day 7, the peak of microglial activity after SNI, has a 
similar function. We hypothesized that the elimination of Trem2-dependent signaling would lead 
to an increase in Iba1 immunoreactivity. To test this hypothesis, we stained L4 spinal cord tissue 
of Trem2-/- mice for Iba1 at several time points after SNI (Fig. 2.12). We found no significant 
difference in the intensity of Iba1 immunoreactivity at any of the selected time points after SNI 



















Fig. 2.12: Time course of the spinal immune response to SNI in Trem2-/- mice 
(A) Representative immunohistochemical staining for Iba1 in the ipsilateral dorsal horn, 
       L4 spinal cord of Trem2-/- and wild-type littermates after SNI (scale bar, 100 µm) 
(B) Semi-quantitative analysis of Iba1 signal intensity normalized to uninjured controls 
       indicated a significant increase in microglial activity after SNI, but no significant 
       difference in signal intensity between genotypes. (p<0.0001 for time in a two-way 




In addition to assessing the impact that removal of Trem2 signaling has on the spinal 
immune response to SNI, we also wanted to determine the extent to which Trem2 modulates the 
development of neuropathic pain-like behavior. To assess pain hypersensitivity after SNI, we 
established the withdrawal threshold to mechanical stimulation of the hind paw with calibrated 
von Frey filaments. Neuropathic pain-like behavior in rodents is characterized by a marked 
decrease in the threshold to normally painless levels of stimulation, equivalent to mechanical 
allodynia in humans. Both Trem2-/- mice and wild-type littermates exhibited a rapid decrease in 
the mechanical force eliciting withdrawal responses when applied to the affected hind paw. Slope 
and extent of the threshold change did not differ between Trem2-/- and Trem2+/+ mice, suggesting 
that the removal of Trem2 signaling does not affect the development of neuropathic-pain like 












Fig. 2.13: Trem2 deletion does not affect SNI-induced 
mechanical allodynia. 
Withdrawal responses to mechanical stimulation with von 
Frey filaments after SNI in Trem2-/- mice and wild-type 
littermates. No difference between genotypes was observed in 
the development of neuropathic pain-like behavior when 
compared using a two-way ANOVA (n=5; data are 
represented as mean ± SEM). 
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Our results demonstrated that upregulation of endogenous Trem2 regulates the clearance 
of apoptotic cells, but not the spinal immune response or mechanical allodynia arising in the days 
and weeks after SNI. We also aimed to determine whether exogenous activation of the Trem2 
pathway provides any analgesic effect. Because of Trem2’s functional antagonism to Tlr-MyD88 
signal transduction, we hypothesized that enhanced Trem2 signaling has the capacity to reduce 
SNI-induced mechanical allodynia. To induce Trem2-mediated signaling, we took advantage of a 
Trem2-activating antibody (Bio-Rad).  
 Trem2-specific antibodies with demonstrated agonistic properties have been used 
previously to induce Trem2 signaling in microglia (Takahashi et al, 2005). Starting on the day of 
SNI, we intrathecally administered the Trem2 antibody or a control IgG of matching isotype once 
a day for 7 days. The effect on mechanical pain hypersensitivity was measured with von Frey 
filaments. We found no significant difference in the development of neuropathic pain-like behavior 
after SNI between treatments. These findings suggest that exogenous activation of Trem2 is not 










Fig. 2.14: Trem2 activation does not 
prevent the development of 
neuropathic pain-like behavior after 
SNI. 
Withdrawal responses to mechanical 
stimulation with von Frey filaments after 
SNI in C57Bl/6 mice treated with a 
Trem2 activating antibody or IgG control 
(injections indicated with arrows). No 
difference in neuropathic pain-like 
behavior was observed when treatments 
were compared using a two-way ANOVA 





In this chapter, we first established the time course for the spinal immune response in the 
ipsilateral dorsal horn of the spinal cord after SNI. Using RNA sequencing, we discovered 
upregulation of numerous markers of microglial activation. Additionally, we identified increases 
in multiple gene transcripts associated with the Trem2 signaling pathway, previously implicated 
both in the regulation of Tlr-mediated immune responses and microglial phagocytosis. We 
examined the contribution of the Trem2 pathway in spinal microglia to several key aspects of 
peripheral nerve injury-induced neuropathic pain and found a role for microglial Trem2 in the 
phagocytosis of apoptotic cells in the ipsilateral dorsal horn after SNI. However, neither removal 
nor augmentation of Trem2 signaling in the spinal cord affected the overall inflammatory response 
to SNI or the development of mechanical allodynia.  
Our findings challenge the conclusions of a recent study investigating the role of Trem2-
Dap12 signaling in neuropathic pain. Kobayashi et al (2016) suggested that activation of Trem2 
exacerbates pain by eliciting a proinflammatory response. Nevertheless, evidence provided in this 
study seems better suited to characterize the role of the adaptor protein Dap12 rather than Trem2. 
The investigators showed that Dap12-/- animals exhibit significantly less inflammatory cytokine 
expression and mechanical allodynia after L4 spinal nerve transection when compared with wild-
type controls. However, as they acknowledge, Dap12 is a molecular adaptor known to partner with 
numerous cell surface receptors, including Trem1 and macrophage C-type lectin receptor Clec5a. 
The link to Trem2 relied on intrathecal administration of a Trem2 agonist antibody in uninjured 
animals which subsequently provoked mechanical allodynia. However, our results demonstrate in 
a model of peripheral nerve injury that removal of Trem2 signaling does not affect the spinal 
immune response nor development of neuropathic pain-like behavior. Although we cannot rule 
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out the notion that Trem2 activation in the spinal cord of uninjured mice evokes pain, we did not 
find any additional increase in pain hypersensitivity in nerve lesioned mice that we injected with 
a Trem2-activating antibody. Based on our findings, we conclude that the role of Trem2 in spinal 
microglia after nerve injury corresponds to the main function identified in other disease models, 
namely the clearance of apoptotic cells. 
Considering earlier reports of Trem2’s potential to suppress inflammation (Zhang et al, 
2017; Ren et al, 2018; Zhong et al, 2015), we expected intrathecal administration of a Trem2-
activating antibody to reduce microglial activity and indeed, alleviate pain. Our findings do not 
support such a treatment. On the other hand, we did not have direct information regarding 
molecular target engagement in the spinal cord. A more efficient method of Trem2 activation may 
be required to tap into the homeostatic potential of Trem2-Dap12 signaling. Overexpression of 
Trem2 in spinal microglia would be another way of evaluating the treatment potential of 
augmented Trem2 signaling in SNI-induced spinal inflammation.  
The major function that we determined for microglial Trem2 after SNI corresponds to its 
previously reported association with microglia-mediated phagocytosis (Takahashi et al, 2005; 
Hsieh et al, 2009; Kleinberger et al, 2014; Kawabori et al, 2015). As we have recently shown, 
degeneration of dorsal horn neurons contributes to the transition from acute to chronic neuropathic 
pain after nerve injury (Inquimbert et al, 2018). Although modulating the clearance of apoptotic 
cells through Trem2 deletion or activation did not impact the functional outcome in our studies, 
neuronal apoptosis in the spinal cord is notably slow after nerve injury, likely inducing only a mild, 
local inflammatory response. In contrast, the widespread nature of Ab deposits in AD, for example, 
would alternatively suggest that modulation of microglia-mediated phagocytosis in such a context 
may provoke a more severe impact on the course of the disease.  
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Our transcriptome analysis highlighted the magnitude of the inflammatory response in the 
spinal cord to SNI. To better understand the molecular regulation of this response, we needed to 
look more closely at other microglial signaling components, several of which we examine in the 























Cellular components and chemokine regulation of the spinal immune response to SNI 
 
Background and Significance 
Animal models of experimental autoimmune encephalitis (Yamasaki et al, 2014) and spinal 
cord injury (Stirling et al, 2008) have revealed that neuroinflammation in the central nervous 
system may involve immune cells from the peripheral circulation. Mononuclear cells have been 
shown to invade the site of inflammation within the CNS and contribute to the immune response. 
This raises the question of whether immune cells from the periphery invade the dorsal spinal cord 
following nerve injury and, alongside resident microglia, modulate spinal neuroinflammation. 
Microglia are known to expand markedly in the days following peripheral nerve lesion (Suter et 
al, 2009; Calvo et al, 2011; Guan et al, 2016; Okubo et al, 2016; Gu et al, 2016); whether this is 
due solely to proliferation of resident microglia, invasion of peripheral immune cells or both 
remains unclear. 
Recent findings make an invasion of T-cells very unlikely (Gattlen et al, 2016). However, 
earlier studies in bone marrow chimeric mice suggest that circulating monocytes cross the blood-
spinal cord barrier (BSCB) and play a major role in the injury-induced immune response (Zhang 
et al, 2007). Although peripheral nerve injury is known to weaken the BSCB (Echeverry et al, 
2011; Beggs et al, 2010), independent investigations have also demonstrated that the full body 
irradiation used in studies of bone marrow transplants also compromise the integrity of the blood-
spinal cord barrier (Li et al, 2003; Li et al, 2004). Any analgesic therapy targeting the spinal 
immune response to peripheral nerve injury would necessarily need to account for the potential 
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contribution of peripheral immune cells, thus requiring a thorough elucidation of this particular 
investigative question. 
 Examining the cellular composition of the spinal immune response would also be relevant 
for the interpretation of our Trem2-Dap12 findings discussed in Chapter 2. The biochemical 
markers (Cd11b and Cx3cr1) used to identify the cell population expressing Trem2 do not 
differentiate peripheral and central myeloid cells. It is conceivable that peripheral monocytes are 
recruited to the spinal cord after SNI in order to support the clearance of apoptotic cells.  
In this chapter, we use multiple experimental approaches to first determine whether or not 
monocytes from the peripheral circulation invade the dorsal horn after SNI and integrate into the 
observed immune response. We additionally examine the relative contribution of multiple immune 
response pathways using a combination of genetic and pharmacological tools to assess the extent 
to which targeting chemokine and growth factor signaling individually and simultaneously can 
impact the spinal immune response to SNI and the ensuing behavioral pain phenotype.  
Peripheral and central myeloid cells possess different expression patterns of chemokine 
receptors. The role of chemokines in regulating the spinal immune response to peripheral nerve 
injury has been intensely studied, because targeting these receptors may lead to the discovery of 
treatment approaches directed at the recruitment of these immune cells. Early investigations into 
the spinal immune response explored a possible link between neuronal signaling and the spinal 
immune cells reacting to the injury. Fractalkine signaling is a prime example of direct 
neuroimmune crosstalk, because within the central nervous system, fractalkine is primarily 
expressed by neurons and its only known receptor, Cx3cr1, is present primarily in microglia 
(Harrison et al, 1998; Jung et al, 2000).  
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Fractalkine has in fact been linked to one integral component of purinergic signaling in the 
dorsal spinal cord. ATP emanating from damaged afferent nerve fibers activates the P2x7 receptor 
on spinal microglia, causing the 
downstream secretion of cathepsin S 
(Clark et al, 2010). A lysosomal protease, 
CatS cleaves the chemokine fragment of 
membrane-bound fractalkine from the 
surface of neighboring spinal neurons 
(Fig. 3.1; Clark et al, 2007; Clark et al, 
2009). Once enzymatically released, 
soluble fractalkine (sFKN) binds to 
Cx3cr1 on microglia. Activation of 
Cx3cr1 induces phosphorylation of p38 MAPK and the subsequent release of pro-inflammatory 
factors like nitric oxide (NO) and interleukins 1b and 6 (IL-1b and IL-6) (Clark et al, 2007). 
Peripheral nerve injury models cause an increase in sFKN in the dorsal horn of the spinal 
cord (Clark et al, 2009; Staniland et al, 2010). These findings, combined with experimental results 
showing that intrathecal administration of FKN- or Cx3cr1-neutralizing antibodies can reduce 
neuropathic pain-like behavior, suggest that fractalkine signaling in the dorsal horn after nerve 
injury is a pro-nociceptive process (Milligan et al, 2004; Clark et al, 2007). This hypothesis is 
further supported by a partial decrease in microglial reactivity after partial nerve ligation (PNL) in 
mice lacking the Cx3cr1 receptor and a deficit in neuropathic pain-like behavior in these same 
knockout animals (Staniland et al, 2010).  
Figure 3.1: Schematic representation of ATP-
induced CatS release, resulting in the cleavage of 
membrane-bound FKN (Clark et al, 2012). 
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We decided to examine the contribution of fractalkine signaling to the spinal immune 
response induced by SNI. Although fractalkine is an established downstream effector of P2x7 
receptor activation, ATP stimulation of P2x4 receptor signaling is a key mechanism contributing 
to neuropathic pain-like behavior, as previously described (see Figures 1.3 and 1.4). To also 
investigate the possibility of P2x4r-mediated effects of ATP, we utilized NP-1815-PX, a newly 
developed P2x4r-specific antagonist provided by Nippon Chemiphar.  
Additionally, peripheral nerve injury is known to induce significant upregulation and 
release of Csf1 from injured afferent nerve fibers, as described in Chapter 1 (Guan et al, 2016). 
Both proliferation and activation of the resident microglia population is affected by this influx of 
Csf1 (Guan et al, 2016). Within the CNS, the Csf1 receptor is exclusively expressed by microglia 
and is in fact upregulated in the ipsilateral dorsal horn after peripheral nerve injury (Guan et al, 
2016). These data, in combination with the established impact of Csf1 on neuroinflammation and 
neuropathic pain-like behavior after nerve injury, suggest that preventing increased spinal 
immunoreactivity in the days following nerve lesion by disrupting Csf1r signaling can prevent the 
induction of neuropathic pain. Indeed, previous studies have demonstrated that prolonged blockade 
or removal of Csf1r signaling severely depletes myeloid cell populations, including microglia 
(Erblich et al, 2011; Rice et al, 2015). To this end, Plexxikon, Inc. has developed several 
formulations of Csf1r antagonists. In this chapter, we utilize one of these compounds to selectively 
deplete myeloid cell populations as a way to also examine the impact of microglial depletion on 






The spinal immune response consists primarily of resident microglia 
To clarify whether monocytes from the peripheral circulation invade the dorsal horn of the 
spinal cord after SNI, we used several technical approaches. We first generated a transgenic mouse 
line that expresses green fluorescent protein (GFP) under the control of the Cx3cr1 promoter and 
red fluorescent protein (RFP) under the control of the Ccr2 promoter by cross-breeding 
homozygous mice from two commercially available transgenic lines (Cx3cr1GFP/GFP and 
Ccr2RFP/RFP respectively). The gene encoding the fractalkine receptor (Cx3cr1) is expressed in both 
microglia and monocyte populations, while Ccr2 is a cell surface receptor predominately expressed 
in monocytes. These Cx3cr1+/GFP-Ccr2+/RFP mice thus express GFP in both monocytes and 
microglia, but express RFP exclusively in monocytes. We examined the immunoreactivity for both 
signals in L4 spinal cord tissue from these transgenic mice 7 days after SNI compared to uninjured 
controls. While we saw robust induction of Iba1 immunoreactivity in the ipsilateral dorsal horn, 
we found no RFP signal, suggesting that blood monocytes did not invade the spinal cord (Fig 3.2). 
 
 
Fig. 3.2: SNI does not lead to invasion of Ccr2+ monocytes into the ipsilateral 
dorsal horn in Cx3cr1+/GFP-Ccr2+/RFP mice. 
Representative immunohistochemical staining of the L4 spinal cord from Cx3cr1+/GFP-
Ccr2+/RFP mice. Tissue from mice 7 days after SNI was compared with uninjured 
controls. No RFP+ monocytes were found in the ipsilateral dorsal horn after SNI (n=5; 
scale bar, 100 µm). 
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Next, we isolated immune cells from ipsilateral spinal segments L4-L5 and stained for 
surface markers that distinguish between resident microglia and monocytes to enable the 
differentiation of these populations by flow cytometry. For this purpose, we stained for Cd11b (a 
cell surface receptor expressed across all myeloid cells), Cx3cr1 and Ccr2. We examined levels of 
Ccr2 expression in Cd11b+/Cx3cr1+ cells isolated from mice 7 days after SNI, the timepoint we 
previously determined to be the peak of the immune response, compared with uninjured mice. We 
found no significant difference in the expression levels of Ccr2 within this cell population when 
compared to uninjured controls (Fig 3.3). Taken together, our findings suggest that monocytes 








































Fig. 3.3: Differentiation of spinal immune cells by flow cytometry 
(A) Flow cytometry analysis of uninjured (upper) and 7 days after SNI (lower) ipsilateral L4 
       spinal cord. 
(B) SNI did not induce significant change in the proportion of Ccr2+ cells within the 
       Cd11b+/Cx3cr1+ population in ipsilateral spinal cord when compared with uninjured 
       controls using Student’s t test (tissue from 2 mice was pooled per sample; n=4; data 
       represented by mean ± SEM). 
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Fractalkine signaling is not a critical modulator of neuropathic pain 
 Using DAVID (see Fig. 2.7), we identified an upregulation of several chemokine signaling 
pathways (p<0.001) at the peak of the immune response 7 days after SNI. Notably, the gene 
encoding the fractalkine receptor (Cx3cr1) increased 2.9-fold (p<0.001) 7 days after SNI, 
suggesting a potential involvement of the fractalkine signaling pathway in the spinal immune 









Fig. 3.4: Upregulation of chemokine signaling 
molecules. 
(A) Pathway analysis (DAVID) of chemokine 
       signaling after SNI (p<0.01). Heatmap of genes 
       associated with chemokine signaling (all p<0.01). 
(B) SNI induces a marked upregulation of the gene 
       encoding the fractalkine receptor (Cx3cr1) as 
       determined by quantitative real-time (qRT) PCR 
       analysis (n=3-4; ***p<0.001 in Student’s t test). 
       qPCR results presented as mean fold change of 
       DCT ± SD after normalization to Gapdh, relative 
       to uninjured control samples. 
A B 
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We assessed the impact of this pathway on both the spinal immune response and 
mechanical allodynia induced by SNI. We first harvested spinal cord tissue from animals either 
heterozygous or homozygous for a deletion of the Cx3cr1 gene 7 days after SNI. In these mice, 
GFP is expressed in place of the endogenous Cx3cr1 gene. We stained L4 spinal cord tissue for 
Iba1 immunoreactivity to determine any changes in the microglial response. A semiquantitative 
analysis of the immunofluorescent signal did not indicate a difference in the intensity of the 
immune response of either genotype when compared with wild-type controls (Fig. 3.5). These 
results suggest that disrupting fractalkine signaling in spinal microglia does not change the level 







Fig. 3.5: Disruption of fractalkine signaling does not alter the spinal immune response to 
SNI 
(A) Representative immunohistochemical staining for Iba1 in the ipsilateral dorsal horn, L4 
       spinal cord of Cx3cr1GFP/GFP, Cx3cr1+/GFP and Cx3cr1+/+ mice 7 days after SNI (scale bar, 
       100 µm). 
(B) Semi-quantitative analysis of Iba1 signal intensity normalized to wild-type mouse signal 
       indicated no significant difference in Iba1 fluorescence between genotypes when compared 
       using a one-way ANOVA (n=4; data represented as mean ± SEM). 
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We then assessed pain hypersensitivity in these animals after nerve injury. After 
establishing a baseline withdrawal threshold to mechanical stimulation with calibrated von Frey 
filaments, Cx3cr1GFP/GFP and Cx3cr1+/GFP mice were tested at multiple intervals after SNI to 
compare the development of neuropathic pain-like behavior with wild-type littermates. 
Homozygous, heterozygous and wild-type mice all demonstrated a rapid decrease after SNI in the 
mechanical force eliciting withdrawal responses when von Frey filaments were applied to the 
affected hind paw (Fig. 3.6). Slope and extent of the threshold change did not differ between 
genotypes. Contrary to previous reports, fractalkine signaling did not appear to regulate the 















Fig. 3.6: Mechanical allodynia after SNI develops 
independently of fractalkine signaling. 
Withdrawal responses to mechanical stimulation with von Frey 
filaments after SNI in Cx3cr1GFP/GFP, Cx3cr1+/GFP and 
Cx3cr1+/+ mice. No significant difference between genotypes 
was found in the development of pain-like behavior when 
compared using a two-way ANOVA (n=10; data are 
represented as mean ± SEM). 
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Reducing microglia does not prevent the development of neuropathic pain 
Csf1 is an essential growth factor necessary for microglial viability and survival within the 
CNS. Blockade of Csf1r signaling in microglia has been shown to induce cell death and, in vivo, 
leads to the large-scale depletion of the resident microglial cell population (Erblich et al, 2011; 
Rice et al, 2015). After determining a 2.9-fold upregulation of Csf1r mRNA in the ipsilateral dorsal 
horn after SNI using qRT-PCR (suggesting a role for Csf1 signaling in the spinal immune 
response), we utilized PLX5622, a recently developed Csf1r antagonist, to disrupt Csf1r-mediated 
signaling in vivo. Mice were fed chow formulated with PLX5622 (or control chow) for 3 weeks 
prior to behavioral testing and SNI to allow for full depletion of microglia. Treatment continued 
until the experimental endpoint. Mice on PLX5622 for 3 weeks showed a near complete depletion 













Fig. 3.7: PLX5622 depletes resident microglia in the spinal cord of uninjured mice 
(A) SNI induces a marked upregulation of the gene encoding the Csf1 receptor (Csf1r) as 
       determined by quantitative real-time (qRT) PCR analysis (n=3-4; ***p<0.001 in 
       Student’s t test). qPCR results presented as mean fold change of DCT ± SD after 
       normalization to Gapdh, relative to uninjured control samples. 
(B) Representative immunohistochemical staining for Iba1 in the ipsilateral dorsal horn, L4 
       spinal cord of uninjured C57Bl/6 mice treated with PLX5622 or control chow (scale bar, 
       100 µm). 
(C) Semi-quantitative analysis of Iba1 signal intensity demonstrated a marked decrease in 
       Iba1 immunoreactivity following PLX5622 treatment in a Student’s t test (n=4; 
       ***p<0.001; data represented as mean ± SEM). 
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To assess the efficacy of microglial depletion, we stained for Iba1 in L4 spinal cord sections 
from mice 7 days after SNI. We found a slight activation of remnant microglial cells relative to 
uninjured mice on PLX5622. However, reactivity 7 days after SNI was vastly diminished when 




















Fig. 3.8: PLX5622 prevents microglial activation after SNI 
(A) Representative immunohistochemical staining for Iba1 in the ipsilateral dorsal horn, L4 
       spinal cord of Cx3cr1GFP/GFP and Cx3cr1+/+ mice fed PLX5622 or control chow, 7 days 
       after SNI (scale bar, 100 µm). 
(B) Semi-quantitative analysis of Iba1 signal intensity normalized to signal in wild-type 
      mice on control chow indicated significantly less Iba1 fluorescence in both genotypes 
      when treated with PLX5622, but not control chow, as determined by two-way ANOVA 
      (n=3-4; ***p<0.001 for treatment effect, genotype had no significant effect; data 






We also treated Cx3cr1GFP/GFP mice with PLX5622 to determine if combined disruption of 
microglial recruitment would alter the development of neuropathic pain-like behavior. 
Cx3cr1GFP/GFP mice on PLX5622 demonstrated similar levels of Iba1 immunoreactivity 7 days after 
SNI to wild-type controls, a significantly less robust signal than mice on control chow (Fig. 3.8).  
Despite clear reduction of the microglial cell population prior to SNI and minimal reactivity 
by 7 days after nerve injury, testing for mechanical allodynia using von Frey filaments did not 
demonstrate a difference in the behavioral phenotype between either genotype on PLX5622 and 
















Fig. 3.9: Depletion of microglia via PLX5622 does not reduce 
mechanical allodynia after SNI. 
Withdrawal responses to mechanical stimulation with von Frey 
filaments after SNI in Cx3cr1GFP/GFP mice and wild-type 
littermates treated with PLX5622 or control chow. No 
difference between genotypes or treatment regimen was found 
when compared using a two-way ANOVA (n=5-10; data are 
represented as mean ± SEM). 
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Blockade of microglial P2x4r signaling mitigates neuropathic pain 
 P2x4 receptor signaling has been established as a key regulatory pathway of microglial 
activity in the spinal cord (Tsuda et al, 2003; Ulmann et al, 2008). To determine whether ATP 
stimulation of the P2x4 receptor in microglia contributes to SNI-induced mechanical allodynia, 
we utilized NP-1815-PX, a novel selective antagonist of the P2x4 receptor. Because NP-1815-PX 
has limited CNS penetrability (Matsumura et al, 2016), we administered the compound 
intrathecally and examined pain-like behavior within 3 hours of the injection.  
 We tested for mechanical allodynia using von Frey filaments on days 3, 7 and 10 after SNI. 
On day 3, we established the neuropathic pain-like phenotype. On day 7, we repeated the 
stimulation with von Frey filaments following an injection of NP-1815-PX (30 pmol) to test 
efficacy. Intrathecal administration of NP-1815-PX on day 7 after SNI partially reversed 
neuropathic pain-like behavior in Cx3cr1+/+ mice. On day 10, we evaluated the mice again without 
administering the antagonist and found no sustained effect of NP-1815-PX (Fig. 3.10). The pain 
phenotype of previously treated mice was indistinguishable from mice injected with vehicle. 
To determine whether the analgesic effect of the P2x4r antagonist was mediated by 
microglia, we conducted our experiment on Cx3cr1+/+ mice on control chow as well as 
Cx3cr1GFP/GFP mice on PLX5622. We found no significant analgesic effect of NP-1815-PX in 
microglia-depleted Cx3cr1GFP/GFP mice (Fig. 3.10). These findings demonstrate that unlike wild-
type mice on control chow, mice with depleted microglia show no reversal of neuropathic pain-
like behavior upon administration of the P2x4r antagonist on day 7 after SNI, suggesting that the 










































































































   
   











































   





























































   











































   






























   






































In this chapter we used a multipronged experimental strategy to examine whether or not 
monocytes circulating in the blood invade the dorsal horn of the spinal cord after SNI. The 
complete absence of these cells dismissed the notion that Ccl2, an essential chemokine for 
peripheral monocyte and macrophage recruitment, is involved in the innate immune reaction to 
nerve injury. We concluded that resident microglia are solely responsible for the inflammatory 
response and examined prominent pathways regulating the activity of this innate immune cell 
population. Using a pharmacogenetic approach, we examined the ability of fractalkine signaling 
to regulate both the spinal immune response and neuropathic pain-like behavior associated with 
SNI. We then utilized small molecule inhibitors to selectively disrupt P2x4r signaling and deplete 
microglia in the CNS. These experiments allowed us to assess the impact of purinergic signaling 
individually and in combination with myeloid cell depletion on the development of mechanical 
allodynia after SNI. 
The question of monocyte invasion has been addressed in several recent publications 
involving nerve injury models. A previous transcriptomic analysis of the spinal cord after nerve 
injury revealed significant upregulation of select microglia-enriched genes, but, similar to our 
findings, no changes in monocyte-enriched genes after peripheral nerve injury (Guan et al, 2016). 
Immunohistochemical studies have found aggregation of Ccr2+ cells in the L4 dorsal root ganglion 
after SNT, but no evidence of these cells in the dorsal horn of the spinal cord (Kobayashi et al, 
2016). These findings corroborate our immunofluorescent work showing no RFP+ monocytes 
invading the dorsal horn after SNI (see Fig. 3.2). In summary, there now exists strong evidence 
from several independent investigations suggesting that the spinal immune response to nerve 
injury does not contain or incorporate any immune cells from the peripheral circulation.  
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However, it is important to acknowledge that monocytes invading local tissue are often 
difficult to track, because they readily acquire the cellular phenotype of resident macrophages. 
While we are confident that our results provide a definitive answer, flow cytometric analyses of 
key monocyte and microglial markers in the dorsal horn at earlier timepoints after nerve injury (in 
the hours and first few days after SNI) may provide additional means of observing these changes 
more closely.  
Our experiments examining key pathways implicated in the regulation of spinal microglia 
further expand our collective understanding of the spinal immune response to SNI. Previous 
reports have shown a partial reduction of microglial activation in the Cx3cr1GFP/GFP mouse after 
peripheral nerve injury (Staniland et al, 2010). In these same studies, no significant differences in 
mechanical allodynia were observed between sham-operated and PNL-operated KO animals after 
injury, suggesting that activation of this pathway was essential for the development of injury-
induced mechanical allodynia. These results were recently recapitulated in the context of the spinal 
nerve transection (SNT) model of neuropathic pain (Gu et al, 2016). Although the mouse strain is 
consistent between our sets of experiments, we have here provided the first reported microglial 
activity and behavioral analysis of these mice in the SNI model of neuropathic pain. While both 
models have historically been used to study neuropathic pain, the surgical differences between 
models may potentially account for some of the discrepancies we observed in the cellular and 
behavioral phenotypes after SNI, although such differences across neuropathic pain models have 
not been extensively studied and would thus warrant further investigation.  
Interestingly, multiple investigations into the role of fractalkine signaling in other 
experimental models involving neurodegeneration demonstrate an anti-inflammatory effect of 
microglial Cx3cr1 stimulation, showing reduced production of inflammatory cytokines (Tang et 
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al, 2014; Cho et al, 2011; Pabon et al, 2011). That said, our findings overall do not support a major 
role for fractalkine signaling in spinal microglia after nerve injury. 
Fractalkine signaling is but one downstream effect of ATP signaling observed after 
peripheral nerve injury. Activation of the P2x7 receptor by ATP triggers the phosphorylation of 
p38 MAPK in microglia which induces the downstream secretion of CatS, the protease responsible 
for the extracellular cleavage of membrane-bound fractalkine (Clark et al, 2010; Clark et al, 2012). 
However, phosphorylated p38 MAPK signaling has also been linked to a shift in microglial 
phenotype attributed to Irf8-mediated transcription (Masuda et al, 2012). Irf8 is known to regulate 
the transcription of several factors defining the inflammatory phenotype of microglia, including 
Cx3cr1, Ctss, P2rx4, Bdnf and Csf1r (Masuda et al, 2012). Intervention targeting higher-level 
signaling may thus be required to reduce microglial reactivity. To this end, antagonists of the P2x7 
receptor are currently being developed (Bhattacharya et al, 2016) and will shed light on the 
potential function of this receptor as a regulator of microglial reactivity.  
The most intriguing result from this series of experiments is the lack of any impact on 
neuropathic pain-like behavior following the near-complete depletion of spinal microglia. More 
research will be required to fully understand the pathophysiological consequences of these 
findings. One explanation for these data would be that the spinal immune response to nerve injury 
does not actually play a significant role in the development of SNI-induced mechanical allodynia. 
This interpretation would be counter to a number of previous studies that have linked mitigation 
of the immune response to less neuropathic pain-like behavior (Guan et al, 2016; Lee et al, 2018; 
Echeverry et al, 2017). Specifically, a recently published study using a different method of 
microglial depletion in the context of the SNT model of neuropathic pain is noteworthy (Peng et 
al, 2016). In their mouse model, Peng et al used tamoxifen (TM)-controlled Cre recombinase 
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expression to conditionally express the diphtheria toxin receptor (DTR) in Cx3cr1+ cells. 
Subsequent ablation of spinal microglia by treatment with the diphtheria toxin was shown to 
abolish both mechanical and thermal hypersensitivity after SNT.  
Notably, microglial activity was diminished in both of our studies and indeed both methods 
of microglial depletion induce cell death, which may in turn cause a local inflammatory response. 
However, depletion of microglia via our PLX5622 treatment paradigm was gradual and took place 
over the course of 3 weeks prior to nerve injury, whereas diphtheria toxin-induced cell death occurs 
rapidly, leading to ablation of microglia within 1-3 days. The significance of the different temporal 
dynamics observed in these ablation paradigms is unknown. Depletion of microglia with PLX5622 
over several weeks would potentially allow for prolonged adaptive changes in the spinal 
microenvironment in contrast to the acute ablation of this cell population. Alterations in the 
proteomic composition and function of glutamatergic synapses have been previously reported in 
microglia-depleted mice (Parkhurst et al, 2013), although the relevance to nerve injury has yet to 
be investigated.  
Lower doses of PLX5622 (roughly 300 mg/kg versus the 1200 mg/kg used in our studies) 
starting only 2 days prior to partial sciatic nerve ligation (PSNL) reduced microglial activation in 
the ipsilateral dorsal horn and, in contrast to our findings, were associated with a partial decrease 
in mechanical allodynia (Lee et al, 2018). In this study, investigators intentionally avoided 
complete depletion of the microglial population and their findings in fact support the idea that 
disruption of Csf1r signaling can impact the development of neuropathic pain-like behavior after 
peripheral nerve injury, as previously reported in Guan et al, 2016. 
The analgesic effect of the P2x4r antagonist NP-1815-PX supports previous reports that 
ATP activation of P2x4r plays an important role in neuropathic pain (Tsuda et al, 2003; Coull et 
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al, 2005; Masuda et al, 2014). As described in Chapter 1 (see Fig. 1.3), activation of P2x4r after 
peripheral nerve injury induces the secretion of Bdnf from activated microglia, which subsequenty 
induces a depolarizing shift in the chloride reversal potential of neighboring inhibitory 
interneurons (Coull et al, 2005). This shift reduces the efficacy of fast synaptic inhibition through 
GABAA and glycine receptors, thus altering the carefully controlled balance of neurotransmission 
in nociceptive signaling pathways of the dorsal horn. Intrathecal administration of NP-1815-PX 
demonstrated the acute analgesic efficacy of ATP-P2x4r inhibition. Whether this effect is due 
directly to the Bdnf-mediated impact on inhibitory interneurons has yet to be fully investigated, 
but our results support P2x4r as a promising therapeutic target for neuropathic pain. 
Alternatively, the lack of therapeutic effect in microglia-depleted mice may indicate that 
spinal microglia serve a supportive physiological role after SNI in addition to the mediation of 
inflammation. As discussed in Chapter 2, the characterization of microglial activation as 
neuroprotective or neurotoxic in instances of neurodegeneration has yet to be fully elucidated in 
the context of peripheral nerve injury. Assessing the contribution of master transcriptional 
regulators of microglial phenotype, a few of which are discussed in the following chapter, to nerve 
injury-induced inflammation may provide greater insight into the therapeutic potential of targeting 










Conclusions and Research Outlook 
 
 One pathophysiological hallmark of peripheral nerve injury is the induction of a vivid 
innate immune response in the dorsal horn of the spinal cord. Although this neuroinflammatory 
reaction has been extensively studied in recent years, the exact cellular and molecular mechanisms 
underlying the immune response remain incompletely understood and clinically efficient 
pharmacotherapies targeting this reaction have yet to be developed. Elucidating key 
immunoregulatory signaling pathways in spinal microglia is essential for understanding how to 
properly modulate this immune response as a means of treating neuropathic pain. 
We have examined the contribution of microglia to peripheral nerve injury-induced 
neuroinflammation and mechanical allodynia, one of the key features of neuropathic pain in 
humans. As described in Chapter 2, we discovered a role for microglial Trem2 in the phagocytic 
clearance of apoptotic cells after SNI. We recently published a study establishing neuronal 
apoptosis in the ipsilateral dorsal horn of the spinal cord as a key mechanism driving the transition 
from acute to chronic pain after nerve injury (Inquimbert et al, 2018). Here we demonstrate that 
microglial Trem2 signaling is necessary for the removal of these apoptotic cells. In collaboration 
with Hynek Wichterle from the Department of Pathology and Cell Biology at Columbia 
University, we are currently establishing an in vitro model to further elucidate the key downstream 
signaling partners of Trem2 involved in the regulation of microglial phagocytosis. Our model will 
utilize stem cell-derived inhibitory interneurons and co-cultured primary microglia to study the 
phagocytosis of apoptotic cells following an excitotoxic challenge. This model will also facilitate 
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research on the molecular determinants that define the vulnerability of inhibitory interneurons to 
excitotoxic cell death.  
Several recent studies have provided evidence showing that mitigation of the spinal 
immune response can reduce neuropathic pain-like behavior after nerve injury (Guan et al, 2016; 
Lee et al, 2018). Here we present new findings that demonstrate the microglial reaction to 
neurodegeneration is one component of this neuroinflammatory process. In fact, the role of 
microglia in the context of neurodegenerative disease has become the central topic of much 
research in recent years. Whether neuroinflammation creates a neurotoxic environment or actually 
serves a physiological and ultimately neuroprotective role by clearing cellular debris and protein 
aggregates has been debated in the context of ALS and Alzheimer’s disease (Keren-Shaul et al, 
2017; Wang et al, 2016; Frakes et al, 2014; Re et al, 2014). Although we established an NMDA 
receptor-dependent mechanism of excitotoxic cell death in Inquimbert et al, 2018, the possible 
contribution to this excitotoxicity of inflammatory cytokines secreted by activated microglia has 
not yet been studied. A thorough understanding of changes induced by neuronal apoptosis to the 
cellular environment of the spinal dorsal horn will be essential to the future development of 
neuroprotective therapeutics. 
One of our key findings is the lack of impact on the spinal immune response and SNI-
induced mechanical allodynia we achieved by individually targeting several key 
immunoregulatory pathways, including Trem2 and fractalkine signaling. In Chapter 3, we present 
evidence that suggests the spinal immune response consists primarily of resident microglia. 
Consequently, we do not expect that targeting the monocyte receptor Ccr2 would affect the 
functional outcome of nerve injury as has been previously reported in studies relying on whole-
body irradiation and bone marrow transplants (Zhang et al, 2007). The increased permeability of 
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the blood-spinal cord barrier induced by such irradiation means that the involvement of Ccr2 
observed in these studies is likely an artifact, a conclusion supported by a recent independent 
reevaluation of monocyte function in neuropathic pain (Peng et al, 2016). However, neither the 
disruption of fractalkine signaling nor the inhibition of Csf1r, both established targets for the 
modulation of microglia (Staniland et al, 2010; Guan et al, 2016), produced analgesia either. 
Perhaps our most striking finding in this series of experiments was the lack of 
consequences on neuropathic pain-like behavior observed after the near-complete depletion of 
microglia. Considering the significant effects reported by other investigators conducting similar 
studies (Lee et al, 2018; Peng et al, 2016), we expected to find at least partial pain alleviation after 
the removal of microglia. One interpretation of our findings would reasonably suggest that the 
spinal immune response is largely irrelevant to the development of SNI-induced mechanical 
allodynia. This conclusion would challenge a host of previous studies demonstrating pain relief 
after the blockade of microglial signaling pathways (Guan et al, 2016; Staniland et al, 2010; Stokes 
et al, 2013). In fact, we also demonstrated a microglia-dependent analgesic effect of the P2x4r 
antagonist NP-1815-PX after SNI. Consequently, the immune response may not be necessary for 
the development of pain, but targeting the neuroinflammatory process that unfolds after nerve 
injury may still hold therapeutic promise (Watkins and Maier, 2003; Ji et al, 2014). An alternative 
interpretation would be that microglial activity is required to maintain a homeostatic 
microenvironment in the days after peripheral nerve injury. In this case, depleting microglia would 
abolish not only inflammation but also disrupt the protective function exercised by spinal 
microglia, ultimately failing to prevent the shift of pain-processing pathways in the dorsal horn 
toward hyperexcitability.  
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Several studies on the physiological functions of microglia support this hypothesis. 
Transforming growth factor-b (TGF-b) is a key microglial growth factor known to maintain these 
cells in a “resting” or homeostatic M0 phenotype (Butovsky et al, 2013; Bohlen et al, 2017). 
Although microglial activation leads to diminished TGF-b expression (Affram et al, 2017), 
intrathecal administration of TGF-b reverses nerve injury-induced spinal inflammation and 
neuropathic pain-like behavior (Echeverry et al, 2009; Chen et al, 2013). In the context of 
peripheral nerve injury, treatment with TGF-b has been shown to mitigate spinal inflammation by 
reducing the phosphorylation of extracellular signal related kinase (ERK) and p38 MAPK, two 
essential kinases linked to the downstream expression of numerous markers of microglial 
activation (Chen et al, 2016).  
Another factor influencing microglial phenotype is PU.1, often considered a master 
regulator of myeloid cell differentiation and development (Vangala et al, 2003; Perdiguero et al, 
2012). Chromatin immunoprecipitation and deep sequencing (ChIP-seq) studies examining direct 
transcriptional targets of PU.1 have shown binding to the promoter regions of nearly every major 
target discussed in this dissertation, including Aif1 (Iba1), Itgam (Cd11b), Csf1, Csf1r, Cx3cr1, 
Tyrobp (Dap12) and Trem2 (Satoh et al, 2014). Other transcriptional modulators of microglial 
phenotype like Irf8 and Runx1 are also subject to PU.1-mediated regulation (Satoh et al, 2014). 
Irf8-/- mice in fact exhibit reduced microglial reactivity and less severe mechanical allodynia after 
peripheral nerve injury when compared with wild-type littermates (Masuda et al, 2012). 
Expression of PU.1 is controlled by the transcription factor CCAAT/enhancer-binding protein-a 
(C/EBP-a). Notably, Csf1 signaling through phosphorylated ERK has been shown to increase 
expression and activity of both PU.1 and C/EBP-a (Smith et al, 2013; Jack et al, 2009). 
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Interestingly, members of this regulatory cascade determining microglial phenotype were 
significantly upregulated after SNI (PU.1: FC=2.7, p<0.001; C/EBP-a: FC=1.4, p<0.05; Irf8: 
FC=2.7, p<0.001; Runx1: FC=2.5, p<0.001), strongly implying that this broad control mechanism 
is activated in the days following nerve injury. Targeting individual downstream response 
pathways, like Trem2 or Cx3cr1, may not produce a sufficient effect on cellular phenotype, 
possibly due to compensation by simultaneously upregulated alternative pathways. 
Mossadegh-Keller and colleagues (2013) have shown that Csf1 directly induces and 
activates PU.1. Guan and colleagues (2016) have further demonstrated that Csf1 released from the 
central terminals of an injured nerve promotes the upregulation of genes linked to PU.1-mediated 
microglial activation. Interestingly, the effects of Csf1 after nerve injury were dependent on 
Dap12. The exact relationship between Dap12 and Csf1r has yet to be fully elucidated, but a role 
for Dap12 in microglial activation and nerve injury-induced pain has been confirmed in multiple 
independent investigations (Guan et al, 2016; Kobayashi et al, 2016). 
Another possible molecular target for upstream therapeutic intervention is microRNA-124. 
An endogenous inhibitor of C/EBP-a, miR-124 has been shown in the context of EAE (Ponomarev 
et al, 2011), Parkinson’s Disease (Yao et al, 2018), intracerebral hemorrhage (Yu et al, 2017) and 
focal cerebral ischemia (Hamzei Taj et al, 2016) to induce a neuroprotective phenotype in 
microglia by promoting microglial quiescence. In fact, daily intrathecal administration of miR-124 
completely prevented the development of neuropathic pain-like behavior after peripheral nerve 
injury (Willemen et al, 2012). Activation of spinal microglia was not assessed in this study, but 
the known effects of miR-124 on C/EBP-a-mediated activation would lead one to hypothesize that 
microglial activation was likely absent in this model. Interestingly, Ponomarev et al, 2011 also 
showed that miR-124 is highly enriched in CNS microglia (relative to peripheral macrophages), is 
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downregulated upon microglial activation and that restoring miR-124 expression results in the 
increased expression of TGF-b in these cells. Taken altogether, a more thorough examination of 
the therapeutic potential of miR-124, including its effect on SNI-induced microglial activation, 
would appear to hold great promise in the treatment of peripheral nerve injury-induced neuropathic 
pain. 
Our results provide new insight into some of the key mechanisms regulating microglial 
phenotype and function in the spinal cord after peripheral nerve injury. Resolving the complex 
interaction of pathways regulating microglial activity after nerve injury will require more work 
however. From a translational perspective, developing safe and effective treatment strategies 
aimed at mitigating spinal neuroinflammation will require highly specific interventions that 
nevertheless deliver a broader cellular effect than can be accomplished by inhibiting a single 
immune response pathway. While our hypothesis that the functional phenotype of microglia can 
be therapeutically manipulated away from an inflammatory activation state toward homeostatic 
functions is intriguing, such a comprehensive approach is likely to require targeting a master 
regulator of the microglial transcriptome. The therapeutic promise of reducing or preventing the 
development of neuropathic pain should necessarily be balanced against the risks associated with 








MATERIALS and METHODS 
 
Animals 
All experimental procedures involving the use of animals were carried out in accordance with the 
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and 
approved by the Institutional Animal Care and Use Committee (IACUC) of Columbia University. 
Mice were housed in a barrier-protected facility with free access to food and water. C57Bl/6J mice, 
Cx3cr1GFP/GFP mice (Jung et al., 2000; strain: B6.129P(Cg)-Ptprca Cx3cr1tm1Litt/LittJ; stock number 
008451) and Ccr2RFP/RFP mice (Saederup et al., 2010; strain: B6.129(Cg)-Ccr2tm2.1lfc/J; stock 
number 017586) were obtained from the Jackson Laboratory. Heterozygous Cx3cr1+/GFP mice were 
generated by cross-breeding homozygous Cx3cr1GFP/GFP mice with wild-type C57Bl/6J mice. 
Heterozygous Cx3cr1+/GFP-Ccr2+/RFP mice were generated by cross-breeding homozygous 
Cx3cr1GFP/GFP mice with homozygous Ccr2RFP/RFP mice. Trem2-/- mice were generously provided 
by Marco Colonna of Washington University in St. Louis, MO. These transgenic strains have been 
bred for >10 generations so that their genetic background was assumed to be equivalent to 
C57Bl/6. All experiments involved adult (8-13 weeks old) male mice.  
 
Genotyping 
DNA for genotyping was extracted from ear punches harvested within the first three weeks of life. 






 Common: 5’-GGTTCCTAGTGGAGCTAGGG-3’ 
 Reverse 1: 5’-TTCACGTTCGGTCTGGTGGG-3’ 
 Reverse 2: 5’-GATCACTCTCGGCATGGACG-3’ 
Ccr2 
 Forward: 5’-TAAACCTGGTCACCACATGC-3’ 
 Reverse 1: 5’-GGAGTAGAGTGGAGGCAGGA-3’ 
 Reverse 2: 5’-CTTGATGACGTCCTCGGAG-3’ 
Trem2 
 Forward 1: 5’-CCCTAGGAATTCCTGGATTCTCCC-3’ 
 Forward 2: 5’-TTACACAAGACTGGAGCCCTGAGGA-3’ 
Reverse: 5’-TCTGACCACAGGTGTTCCCG-3’ 
 
Spared Nerve Injury (SNI) 
Surgery for spared nerve injury (SNI) was performed as previously described (Decosterd et al., 
2000). Under 2.5% isoflurane anesthesia, an incision of < 1 cm in length was made in the left leg 
to expose the trifurcation of the sciatic nerve into the tibial, common peroneal and sural nerves. 
The tibial and common peroneal branches were tightly ligated using 6-0 nylon sutures (Ethicon) 
and transected distal to the site of ligation, leaving the sural branch intact (spared). Connective 
tissue and muscle were sutured using 5-0 Vicryl monofilament (Ethicon). Wound clips and 





Drugs were intrathecally administered as previously described (Njoo et al., 2014). Under 2.5% 
isoflurane anesthesia, the mouse was placed on its ventral side with a small gauze cushion under 
the hips to prop up the lower spine. The L6 spinous process was located through palpation and a 
30G needle with beveled tip (BD Microlance) was used to inject 5 µl of the drug solution into the 
intrathecal space between the L5 and L6 vertebrae. A flick of the tail was used to confirm the entry 
of the needle through the dura and pia mater. 
 
Tissue dissection, cryopreservation and sectioning 
Under deep (5%) isoflurane anesthesia, mice underwent a thoracotomy and transcardiac perfusion 
with 50 ml of DPBS without divalent cations (DPBSw/o, Invitrogen, catalog number 14190-235) 
containing 2mM EDTA then with 50 ml of 4% paraformaldehyde (PFA). Lumbar segments L4 
and L5 of the spinal cord were then dissected, post-fixed in 4% PFA for 2 hours at 4°C and 
incubated in 30% sucrose overnight at 4°C. The following day, tissue was removed from the 30% 
sucrose solution, dried to remove any excess sucrose solution, embedded in Tissue-Tek OCT 
(VWR), flash-frozen over liquid nitrogen and stored in -80°C. Frozen, embedded spinal cord tissue 
was then cryosectioned into 10 µm thick tissue sections using a Leica CM3050S cryostat and 
stored at -80°C. 
 
Immunohistochemistry (IHC) 
Cryosections of 10 µm thickness from lumbar segment L4 of the mouse spinal cord were gradually 
brought to room temperature from -80°C before being briefly rinsed with PBS. Nonspecific protein 
binding sites were blocked for 1 hour at room temperature using 10% goat serum (ThermoFisher 
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Scientific) in PBS with 0.1% Triton X-100 (Sigma). After blocking, sections were incubated 
overnight at 4°C with primary antibody (see “Antibodies” for specific dilutions) and subsequently 
washed 3 times for 5 minutes each in PBS at room temperature (20-25°C) on a shaker set to 55rpm. 
Sections were incubated for 45 minutes at room temperature with secondary antibody (see 
“Antibodies” for specific dilutions) and washed again 3 times for 5 minutes each in PBS prior to 
mounting in either Vectashield (Vector Laboratories) or Prolong Gold (ThermoFisher). All 
immunohistochemistry presented throughout was generated following this protocol unless 
otherwise noted.  
 
Immunocytochemistry (ICC) 
Immunoselected microglia harvested and isolated as described above were cultured for 7 days on 
poly-D-lysine coated glass coverslips at a density of 120,000 cells/ml. Cells were then fixed with 
4% paraformaldehyde in PBS for 20 minutes at room temperature (20-25°C) and subsequently 
washed 3 times for 5 minutes each in PBS before being incubated with blocking solution (10% 
goat serum in PBS with 0.1% Triton X-100) for 1 hour at room temperature. After blocking, cells 
were then incubated overnight in 4°C with primary antibody (see “Antibodies for specific 
dilutions) before being washed 3 times for 5 minutes each with PBS. Cells were then incubated 
for 40 minutes at room temperature with secondary antibody (see “Antibodies” for specific 
dilutions), washed 3 times for 5 minutes each in PBS and mounted onto glass slides using 





Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
L4 segments from mouse spinal cord were cut into 10 µm cryosections, incubated in a pre-chilled 
(-20°C) mixture of 2:1 ethanol and acetic acid for 5 minutes at -20°C, rinsed twice in pre-chilled 
PBS (4°C) and probed for TUNEL using the ApopTag In Situ Apoptosis Detection Kit (EMD 
Millipore, catalog number S7110) according to the manufacturer’s instructions. Sections were 
incubated with bisbenzimide (H33342; Calbiochem) to counterstain for chromatin and mounted 
using Vectashield (Vector Laboratories) or Prolong Gold (ThermoFisher Scientific). From a 
random starting location within the first 10 cryosections, we selected every tenth section for 
staining and counted TUNEL positive cell profiles in the dorsal horn of the spinal cord. Only 
TUNEL-positive profiles that also demonstrated chromatin changes indicative of apoptosis 
(specifically pyknosis, marginalization or fragmentation) were counted. The total number of cells 
counted in the L4 spinal cord of an animal was normalized to 10 sections for the means reported 
(total counts divided by the number of sections counted multiplied by 10). Within each assay, 
positive control stains were generated using DNase I (Sigma) and negative control stains were 
generated by omitting terminal deoxynucleotidyl transferase from the assay of sections treated 
with DNase I. Immunostaining of TUNEL sections with antibodies against NeuN, Iba1 or both 
was performed after the incubation with ethanol and acetic acid and before probing for TUNEL, 
following our standard protocol for immunohistochemistry. 
 
Confocal Microscopy 
All images were collected using an A1 confocal system (Nikon) equipped with 405 nm (100mW 
fiber output) diode laser; 458, 477, 488 and 514 nm (50 mW) multiline laser, 561 nm (20 mW) 
and 640 nm (100 mW) diode lasers; polarizing beam splitter and 32-channel detector. An Eclipse 
 67 
Ti-E microscope (Nikon), QuantEM 512SC electron-multiplying CCD (EMCCD) camera 
(Photometrics) and NiS-Elements C software (Nikon) were used for acquiring all images at a 
resolution of 1,024 x 1,024 or 2,048 x 2,048 pixels and an image depth of 12 bit. During image 
acquisition, the gain was adjusted to avoid pixel saturation. Artificial colors were generated using 
ImageJ software (Schindelin et al., 2015).  
 
Quantification of immunofluorescence 
Spinal cord sections from 3-4 animals per experimental condition were imaged at an optical 
thickness of 1.0 µm on a confocal microscope. The ipsilateral dorsal quadrant of the spinal cord 
was outlined in ImageJ and the integrated density (fluorescence intensity) of the Iba1 signal within 
this region of interest (ROI) was measured. The integrated density threshold was standardized 
across all images to account for background signal. 
 
Isolation of primary mouse microglia 
Dissection and purification of primary mouse microglia were adapted for the spinal cord from 
previously described protocols (Cardona et al., 2006). Under deep (5%) isoflurane anesthesia, mice 
underwent a thoracotomy and transcardiac perfusion with 50 ml of DPBSw/o containing 2mM 
EDTA. Brain or spinal cord was dissected, the dura removed and the tissue was transferred to 6 
ml of a working enzyme solution containing 0.2% Collagenase Type 4 (Worthington, catalog 
number LS004188) and 2.5mM calcium chloride in RPMI without phenol red + L-glutamine 
(Invitrogen, catalog number 11875-093). We intentionally excluded the enzyme dispase from the 
enzyme solution, because we found that dispase compromises the integrity of some cell surface 
proteins, e.g. Cd11b. Using a sterile razor blade, the tissue was minced in the enzyme solution then 
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incubated for 45 minutes at 37°C, with intermittent trituration using a 1 ml pipette every 10 
minutes. Fifteen minutes before the end of the 45-minute incubation, 120 µl of 2 mg/ml DNase I 
was added to the solution. At the end of 45 minutes, one last trituration was performed and 3 ml 
of DEF solution (5mM EDTA and 1% Fetal Bovine Serum in DPBSw/o) was added to the working 
enzyme solution. An additional 4.5 ml of physiologic Percoll solution [9 parts Percoll (Sigma) and 
1 part 10x DPBSw/o] was added and the cell suspension transferred to a 15 ml falcon tube and 
thoroughly mixed. Then 2 ml of DPBSw/o were carefully added on top of the combined enzyme 
solution creating two distinct layers. The tube was then spun down at 500 g for 30 minutes at 18°C 
with the brake set to 0. Debris and supernatant were aspirated. The pellet was resuspended in 2 ml 
of DPBSw/o and spun down again at 500 g for 7 minutes at 18°C. The supernatant was aspirated 
and the cell pellet was then further processed for cell culture or flow cytometry (see corresponding 
sections below).  
 
Cell culture of primary microglia 
After extraction and enrichment of microglia from the mouse CNS (see above), the cell pellet was 
resuspended in 90 µl of MACS buffer [0.5% Bovine Serum Albumin (Sigma) and 2mM EDTA 
(ThermoFisher Scientific) in DPBSw/o]. Ten µl of anti-Cd11b microbeads (Miltenyi, catalog 
number 130-049-601) were added and mixed. The cells and microbeads-containing suspension 
was incubated at 4°C for 15 minutes with gentle mixing every 5 minutes. After adding 1 ml of 
MACS buffer, the suspension was then spun down for 10 minutes at 300 g at 18°C. After aspirating 
the supernatant, the resulting cell pellet was resuspended in 500 µl of MACS buffer. Using a 
MiniMACS Starting Kit (Miltenyi, catalog number 130-090-312), an MS column was set up in the 
MiniMACS separator attached to the MultiStand and rinsed with 500 µl of MACS buffer. The 500 
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µl of the cells-microbeads suspension were applied through a pre-separation filter (Miltenyi, 
catalog number 130-101-812) to the pre-rinsed column and allowed to flow through completely. 
The column was then rinsed 3 more times with 500 µl of MACS buffer. After removing the column 
from the magnetic holder and out of the magnetic field entirely, 1 ml of MACS buffer was added 
to the column and pushed through forcibly using a column plunger. The cells were spun down for 
10 minutes at 300 g at 18°C. The resulting cell pellet was resuspended in microglia culturing 
medium or MCM [10% FBS (Sigma), 1% Penicillin/Streptomycin (ThermoFisher Scientific), 1% 
Microglia Growth Supplement (ScienCell) in DMEM/F-12 + Glutamax (ThermoFisher Scientific) 
supplemented with 10 ng/ml of recombinant mouse colony stimulating factor 1 (Csf1, R&D 
Systems) and 50 ng/ml of recombinant transforming growth factor-beta (Tgfb, Miltenyi)]. Cells 
were grown on poly-D-lysine-coated 6- or 24-well plates at a density of 120,000 cells/ml. 
 
Flow cytometry 
After extraction of microglia from the mouse CNS (see above), the cell pellet was resuspended in 
100 µl of Cell Staining Buffer (Biolegend, catalog number 420201). TruStain fcX anti-mouse 
CD16/32 (Biolegend, catalog number 101319) was added in a 1:100 dilution as a blocking reagent 
and the suspension was incubated in the dark on ice for 20 minutes. The suspension was 
subsequently diluted in Cell Staining Buffer to obtain aliquots 100 µl per staining condition, 
including IgG control stains. The suspensions were incubated with corresponding conjugated 
antibodies (see “Antibodies” for specific dilutions) in the dark on ice for 30 minutes. When using 
unconjugated primary antibodies, suspensions were further diluted with 1 ml of Cell Staining 
Buffer, centrifuged at 300 g at 4°C for 10 minutes, resuspended in 100 µl of Cell Staining Buffer 
and incubated with fluorescently conjugated secondary antibodies (see “Antibodies” for specific 
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dilutions) in the dark on ice for 20 minutes. After incubation with the respective antibodies, all cell 
suspension samples were diluted with 1 ml of Cell Staining Buffer and centrifuged at 300 g at 4°C 
for 10 minutes. Cell pellets were resuspended in 100 µl of Cell Staining Buffer containing 0.1 µg 
of DAPI and gently mixed. All samples were analyzed on a Beckman Coulter MoFlo Astrios 
FACS machine using Summit software for processing of data. Raw data files were subsequently 
processed in FlowJo software version 10. 
 
Western Blotting 
Protein lysate was extracted from harvested tissue by homogenization using a Potter-Elvehjem 
tissue grinder and a saponin-based lysis buffer consisting of 5 mM Tris-HCl (pH 8.0), 50 mM 
sodium chloride, 0.01% sodium azide, 0.05% saponin, 0.25% triton, 0.25% sodium deoxycholate, 
25mM Tris base, 0.5% Igepal, 0.5mM EDTA in ultrapure milli-Q water containing phosphatase 
inhibitor cocktails 2 and 3 (Sigma, catalog numbers P5726 and P0044) and mini EDTA-free 
protease inhibitor tablet (Roche). Homogenized tissue was incubated in lysis buffer on ice for 30 
minutes, spun down at 4000 g for 30 minutes at 4°C and supernatant containing the protein lysate 
was saved. Protein concentration was determined using the Pierce protein assay and samples were 
prepared with LDS sample buffer and reducing agent (both from ThermoFisher Scientific), such 
that 10 µg of protein were loaded (after denaturation for 5 minutes at 95°C) into each well of a 
NuPAGE 4-12% Bis-Tris protein gel (ThermoFisher Scientific). The electrophoresis chamber was 
filled with MOPS running buffer (ThermoFisher Scientific) and antioxidant added to the buffer 
solution in the inner chamber of the gel box. Samples were run at 170V for 60 minutes before 
being transferred to a polyvinylidene fluoride membrane (EMD Millipore). NuPAGE transfer 
buffer (ThermoFisher Scientific) containing 10% methanol and 0.1% antioxidant was used for the 
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transfer performed at 30V for 60 minutes. Membranes were briefly rinsed in tris-buffered saline 
(TBS) before being incubated with Odyssey blocking buffer (Li-Cor, catalog number 927-40100) 
for 1 hour at room temperature (20-25°C) on a shaker set to 60 rpm. After blocking, membranes 
were incubated in primary antibody diluted in TBS with 0.1% Tween-20 for 2 hours at room 
temperature (see “Antibodies” for specific dilutions) and washed 3 times for 5 minutes each in 
TBS with 0.1% Tween-20. Membranes were then incubated in secondary antibody diluted in TBS 
with 0.1% Tween-20 and 0.02% SDS (see “Antibodies” for specific dilutions) before being washed 
3 times for 5 minutes each in TBS with 0.1% Tween-20. The membranes were imaged using an 
Odyssey CLx system (Li-Cor) and ImageStudioLite software. 
 
RNA extraction and analysis 
Tissue harvested from lumbar segments L4 and L5 of the mouse spinal cord was homogenized in 
QIAzol lysis reagent (Qiagen, catalog number 79306) using a PowerGen 125 tissue homogenizer. 
RNA was extracted and purified using an RNeasy Mini Kit (Qiagen, catalog number 74104) 
according to the manufacturer’s instructions. Tissue from the ipsilateral dorsal horns of L4 and L5 
lumbar spinal cord segments from 2 mice were pooled for each RNA sample. Purity and integrity 
of RNA were verified using the Agilent Bioanalyzer Chip (Columbia Genome Center). RNA 
samples were sequenced by the Columbia Genome Center using a HiSeq2000 system (Illumina). 
The Columbia Genome Center employed the TopHat 2.0.4 algorithm to map reads to the mouse 
genome and the Cufflinks 2.0.2 software program to infer expression level and examine 
differential expression. Functional gene annotations and pathway analyses were performed and 
identified using the Database for Annotation, Visualization and Integrated Discovery or DAVID 
(Huang da W et al., 2009). Figures and graphical representations of RNA sequencing data were 
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generated using GraphPad Prism as well as the GenePattern software (Broad Institute). For 
quantitative real-time (qRT-)PCR analysis, the Applied Biosystems 7500 Quantitative Realtime 
PCR System was used in accordance with the manufacturer’s instructions using Fast SYBR Green 
Master Mix (ThermoFisher Scientific, catalog number 4385612). All qRT-PCR values were 
normalized to Gapdh for analysis. Primers used for qPCR analysis include: 
Trem2 
 Forward: 5’-CGAGAGGCTGAGGTCCTGCAGAAA-3’ 
 Reverse 1: 5’-TGTGTTCCACTTGGGCACCCTCGAAA-3’ 
Tyrobp 
 Forward: 5’-GATTGCCCTGGCTGTGTACTCTCT-3’ 
 Reverse: 5’-GCCTCTGTGTGTTGAGGTCACTGTATACTT-3’ 
Syk 
 Forward: 5’-GAGCAGACGGTCCTCATAGGGTCAAAGA-3’ 
 Reverse: 5’-TCCCTGTCAATGCGGTAGTGCAATACTT-3’ 
Csf1r 
 Forward: 5’-CGAGGGAGACTCCAGCTACAAGAACAT-3’ 
 Reverse: 5’-ACTTGAAGAAGTCGAGACAGGCCTCAT-3’ 
Cx3cr1 
 Forward: 5’-GGTGAGTGACTGGCACTTCCTGCAGAA-3’ 
 Reverse: 5’-CCCAAATAACAGGCCTCAGCAGAATCGTCATA-3’ 
Gapdh 
 Forward: 5’-CACAATTTCCATCCCAGACC-3’ 
 Reverse: 5’-GTGGGTGCAAACTTTAT-3’ 
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Antibodies 
Listed below are antibodies used for IHC, ICC, Western blotting and flow cytometry: 
IHC 
 Cd11b (Bio-Rad, catalog number MCA74G) – 1:500 
 Iba1 (Wako, catalog number 016-26721) – 1:500 
 NeuN (EMD Millipore, catalog number MAB377) – 1:5000 
Goat anti-rabbit Alexa Fluor 488 (ThermoFisher, catalog number A11008) – 1:500 
Goat anti-rabbit Alexa Fluor 594 (ThermoFisher, catalog number A11012) – 1:500 
Goat anti-mouse Alexa Fluor 594 (ThermoFisher, catalog number A11005) – 1:500 
 Donkey anti-rat Alexa Fluor 594 (ThermoFisher, catalog number A21209) – 1:500 
ICC 
 Iba1 (Wako, catalog number 016-26721) – 1:200 
 Trem2 (R&D Systems, catalog number MAB17291) – 1:200 
 Goat anti-rabbit Alexa Fluor 488 (ThermoFisher, catalog number A11008) – 1:400 
 Donkey anti-rat Alexa Fluor 594 (ThermoFisher, catalog number A21209) – 1:400 
Western Blotting 
 Trem2 (Santa Cruz, catalog number sc-48765) – 1:1000 
 b-tubulin III (Sigma, catalog number T8578) – 1:5000 
 Goat anti-mouse 680RD (Odyssey, catalog number 925-68070) – 1:10,000 
 Goat anti-rabbit 800CW (Odyssey, catalog number 925-32211) – 1:10,000 
Flow cytometry 
 TruStain fcX anti-mouse CD16/32 (Biolegend, catalog number 101319) – 1:100 
 APC anti-Cd11b (Biolegend, catalog number 101212) – 1:100 
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 PE anti-Cx3cr1 (Biolegend, catalog number 149005) – 1:100 
 AF647 anti-Ccr2 (Biolegend, catalog number 150603) – 1:100 
 PE anti-CD39 (Biolegend, catalog number 143803) – 1:100 
 PECy7 anti-CD45 (Biolegend, catalog number 103113) – 1:100 
 FITC anti-Ly6c (Biolegend, catalog number 128005) – 1:100 
 Trem2 (R&D Systems, catalog number MAB17291) – 1:200 
 PECy7 goat anti-rat IgG (Biolegend, catalog number 405413) – 1:100 
 APC rat IgG2c isotype control (Biolegend, catalog number 400713) – 1:100 
 PE rat IgG2a isotype control (Biolegend, catalog number 400507) – 1:100 
 PECy7 rat IgG2a isotype control (Biolegend, catalog number 400521) – 1:100 
 FITC mouse IgG2a isotype control (Biolegend, catalog number 400207) – 1:100 
 
The intrathecally administered monoclonal antibody targeting Trem2 (Bio-Rad, catalog number 
MCA4772) as well as the corresponding isotype control antibody (rat IgG1, Bio-Rad, catalog 
number MCA1211) were diluted in sterile saline and injected in a volume of 5 µl for a total 
administration of 1 µg of Ig per injection.  
 
Drugs 
PLX5622: The Csf1r antagonist PLX5622 was provided by Plexxikon, Inc. The drug was 
formulated into AIN-76A irradiated chow at a dose of 1200 mg/kg. To allow for complete 
depletion of microglia, animals were fed PLX5622 for 21 days prior to SNI. Treatment with 
PLX5622-containing chow or AIN-76A control chow was continued after SNI until euthanasia to 
maintain microglial depletion throughout the duration of the study. 
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NP-1815-PX: The P2x4r antagonist NP-1815-PX was provided by Nippon Chemiphar. The 
lyophilized powder was reconstituted into a 6 mM stock. Thirty pmol of NP-1815-PX diluted in 5 
µl of sterile saline were intrathecally injected and all behavioral studies were carried out within 
90-180 minutes of the injection.  
 
Behavioral Tests 
In compliance with the ARRIVE guidelines (Kilkenny et al, 2010), mice were randomly allocated 
to experimental conditions and investigators blinded to the allocation during outcome assessment. 
Mice examined for pain-like behavior were randomly assigned to test boxes. To assess the 
mechanical withdrawal threshold of the mice, calibrated von Frey filaments were applied to the 
plantar surface of the hind paw within the projection territory of the spared sural nerve. The up-
down method was applied for the threshold determination as previously described (Chaplan et al, 
1994). Cold sensitivity was tested by applying a drop of acetone, which produces a cooling 
sensation upon evaporation, to the same region of hind paw and recording the duration of 
withdrawal responses within one minute after the application. Withdrawal responses included 
shaking, licking or biting the affected paw. Prior to SNI, all animals to be used for behavioral 




All statistical tests were performed using GraphPad Prism software Version 7.0. Normal 
distribution of data and equal variances across groups were assumed, but not tested. For 
comparisons of 2 experimental conditions, an unpaired two-tailed Student’s t test was used. For 
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comparisons of > 2 experimental conditions, a one-way analysis of variance (ANOVA) was used, 
followed by Dunnett’s or Tukey’s test for multiple comparisons. To compare different 
experimental conditions over time, a two-way ANOVA was used, followed by Sidak’s or 
Bonferroni’s test for multiple comparisons. Specific details of each statistical analysis can be found 
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